Literature DB >> 11933038

Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data.

Jahar B Choudhury1.   

Abstract

Non-parametric maximum likelihood estimation of the cause specific failure probability, and of its standard error, in the presence of competing risks is discussed with reference to some contraceptive use dynamics data from Bangladesh. The cause specific incidence function provides an intuitively appealing summary curve for failure rates and probabilities, such as probabilities of discontinuation of different kinds of contraception, based on right-censored data of the particular event. Dinse and Larson's formula can be utilized to calculate the standard error of the cause specific probability for the failure type of interest, and to construct pointwise confidence intervals. The accuracy of these intervals, as well as those based on the log(-log) transformation and the arcsine transformation, are compared by simulations. We find that Dinse and Larson's formula, used in conjuction with a log(-log) transform, yields reliable standard error estimates and accurate coverage in samples of small and large size, and can be recommended for use in this situation. Copyright 2002 John Wiley & Sons, Ltd.

Mesh:

Year:  2002        PMID: 11933038     DOI: 10.1002/sim.1070

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  32 in total

1.  Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation.

Authors:  Nandita Khera; Barry Storer; Mary E D Flowers; Paul A Carpenter; Yoshihiro Inamoto; Brenda M Sandmaier; Paul J Martin; Stephanie J Lee
Journal:  J Clin Oncol       Date:  2011-12-05       Impact factor: 44.544

2.  No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.

Authors:  Markus Pfirrmann; Dobromira Evtimova; Susanne Saussele; Fausto Castagnetti; Francisco Cervantes; Jeroen Janssen; Verena S Hoffmann; Gabriele Gugliotta; Rüdiger Hehlmann; Andreas Hochhaus; Joerg Hasford; Michele Baccarani
Journal:  J Cancer Res Clin Oncol       Date:  2017-01-12       Impact factor: 4.553

3.  Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.

Authors:  Stephanie Heon; Beow Y Yeap; Gregory J Britt; Daniel B Costa; Michael S Rabin; David M Jackman; Bruce E Johnson
Journal:  Clin Cancer Res       Date:  2010-10-28       Impact factor: 12.531

4.  Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.

Authors:  G Kunter; J B Perkins; J Pidala; T Nishihori; M A Kharfan-Dabaja; T Field; H Fernandez; L Perez; F Locke; E Ayala; M Tomblyn; J L Ochoa-Bayona; B Betts; M Nieder; C Anasetti
Journal:  Bone Marrow Transplant       Date:  2013-09-02       Impact factor: 5.483

5.  Confidence intervals for the cumulative incidence function via constrained NPMLE.

Authors:  Paul Blanche
Journal:  Lifetime Data Anal       Date:  2018-12-11       Impact factor: 1.588

6.  Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy.

Authors:  Ajay Vora; Anita Andreano; Ching-Hon Pui; Stephen P Hunger; Martin Schrappe; Anja Moericke; Andrea Biondi; Gabriele Escherich; Lewis B Silverman; Nicholas Goulden; Mervi Taskinen; Rob Pieters; Keizo Horibe; Meenakshi Devidas; Franco Locatelli; Maria Grazia Valsecchi
Journal:  J Clin Oncol       Date:  2016-01-11       Impact factor: 44.544

7.  High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up.

Authors:  Robert A Brodsky; Allen R Chen; Donna Dorr; Ephraim J Fuchs; Carol Ann Huff; Leo Luznik; B Douglas Smith; William H Matsui; Steven N Goodman; Richard F Ambinder; Richard J Jones
Journal:  Blood       Date:  2009-12-16       Impact factor: 22.113

8.  Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.

Authors:  Pär Stattin; Erik Holmberg; Jan-Erik Johansson; Lars Holmberg; Jan Adolfsson; Jonas Hugosson
Journal:  J Natl Cancer Inst       Date:  2010-06-18       Impact factor: 13.506

9.  High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia.

Authors:  Christopher J Gamper; Clifford M Takemoto; Allen R Chen; Heather J Symons; David M Loeb; James F Casella; Amy E Dezern; Karen E King; Andrea M McGonigle; Richard J Jones; Robert A Brodsky
Journal:  J Pediatr Hematol Oncol       Date:  2016-11       Impact factor: 1.289

10.  Two-stage sampling designs for external validation of personal risk models.

Authors:  Alice S Whittemore; Jerry Halpern
Journal:  Stat Methods Med Res       Date:  2013-04-16       Impact factor: 3.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.